Dantrolene sodium, ryanodine receptor antagonist (ab142274)

Overview

  • Product name

    Dantrolene sodium, ryanodine receptor antagonist
  • Description

    Ryanodine receptor antagonist. Calcium channel inhibitor
  • Biological description

    Ryanodine receptor antagonist. Calcium channel inhibitor. Reduces calcium flux across the sarcoplasmic reticulum. Displays selectivity for RYR1 and RYR3 over RYR2. Crosses the blood-brain barrier and active in vivo.
  • Purity

    > 98%
  • CAS Number

    14663-23-1
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    3-[(E)-[5-(4-Nitrophenyl)furan-2-yl]methylideneamino]-5-oxo-4H-imidazol-2-olate sodium salt
  • Molecular weight

    336.24
  • Molecular formula

    C14H9N4NaO5
  • PubChem identifier

    6604100
  • Storage instructions

    Store at Room Temperature. The product can be stored for up to 12 months.
  • Solubility overview

    Soluble in water to 5 mM with warming and in DMSO to 10 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    C1C(=O)N=C(N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])[O-].[Na+]
  • Source

    Synthetic

  • Research areas

References

This product has been referenced in:

  • Boys JA  et al. Effects of dantrolene on ischemia-reperfusion injury in animal models: a review of outcomes in heart, brain, liver, and kidney. J Investig Med 58:875-82 (2010). Read more (PubMed: 20517166) »
  • Inan S & Wei H The cytoprotective effects of dantrolene: a ryanodine receptor antagonist. Anesth Analg 111:1400-10 (2010). Read more (PubMed: 20861418) »
  • Zhao F  et al. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 276:13810-6 (2001). Read more (PubMed: 11278295) »
  • Ward A  et al. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 32:130-68 (1986). Read more (PubMed: 3527659) »

Customer reviews and Q&As

Abreviews
IP injection of dantrolen in rat has no effect on EDL weight

Mr. Baptiste Jude

Verified customer

Submitted Jul 20 2016

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up